Keywords: Amgen, Sensipar, Mimpara, Cardiovascular events, Dialysis patients, Ph III

Amgen's Sensipar/Mimpara fails to meet endpoint in CV events for dialysis patients

Article | 11 June 2012

Print This

Amgen (Nasdaq: AMGN), the world’s largest independent biotech company, announced top-line results on Friday of the Phase III ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in